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problems and that at the same time have a high degree of experience 
with both general thoracic, cardiac, vascular and spinal procedures. 
Our policy regarding locally advanced lung cancer patients is to 
perform surgery on ﬁrst intention, whenever a complete resection is 
thought to be technically possible. Complete resection of T4 NSCLC 
results in 40.4% of 5-year survival rate. Patients with NSCLC who 
have carinal involvement, SVC invasion, superior sulcus tumor even 
with vertebral invasion or mediastinal invasion without mediastinal 
lymph node involvement should undergo radical surgery without any 
attempt of giving neoadjuvant chemotherapy. 
The thoracic medical and surgical community should promote all ef-
forts to extend the surgical indications for locally advanced NSCLC, 
making these operations available whenever possible to patients in 
whom radical resection can be achieved.
Figure 1.  Actuarial survival for patients with T4 Non-small Cell Lung Cancer 
undergoing resection, including the operative deaths. The estimated 5-, and 
10-year survivals were 38.4%, and 26%, respectively. A total of 73 patients 
were alive at 5 years, and 25 at 10 years.
Group N
Mortality 
n (%)
5 year 
survival (%)
N0/1 N2+ P
Superior Sulcus 
Tumor
126 1 (0.8%) 36.6 38.5 10.1 0.002
Carinal Invasion 92 6  (6.5%) 42.5 49.8 17.1 0.002
SVC Invasion* 39 3 (7.6%) 29.7 37.5 19.6 0.002
Mediastinal 
Invasion
14 1 (7.1%) 59.3 55.6 7.5 0.002
TOTAL 271 11 (4.05%) 38.4 43 17.7 0.002
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The goal of Image Guided Radiation Therapy (IGRT) is the delivery 
of higher doses to tumors without delivering as high doses to normal 
tissues or, conversely delivering the desired dose to the tumor and 
reducing the dose to normal tissues. IGRT is a term that has evolved 
over that last decade. This is exempliﬁed by the activities of the IGRT 
Committee of the Radiation Therapy Oncology Group which was 
established around that time. The ﬁrst focus was on 3-dimensional 
radiation therapy (3D CRT), a development that was fostered by grants 
from the National Cancer Institute in the 1980’s. These grants led to 
new tools that permitted 3-dimensional reconstructions of axial images 
from computed tomography and development of 3-dimensional radia-
tion dose distributions including heterogeneity corrections. Treatment 
planning systems (TPS) were developed in research institutions that 
stimulated industry to develop TPS: these became available between 
1993 and 1995. A grant from NCI led to creation of a reference and 
archival center at Washington University in St. Louis to which images 
could be sent and stored. This centered on 3D CRT for cancer of the 
prostate, but eventually expanded to other disease sites. Other reference 
centers developed and eventually coalesced into the Advanced Technol-
ogy Consortium (ATC) that serves as a resource for many forms of 
advanced radiation treatment technologies today. 
Physicists, engineers and equipment manufacturers developed the abil-
ity to plan and deliver intensity modulated radiation therapy (IMRT) 
whereby beamlets could be delivered with different intensities to 
shape radiation dose distributions even more precisely, giving higher 
doses to tumors and lesser doses to surrounding normal tissues. 3D 
CRT was adopted very quickly in the radiation oncology community 
whereas IMRT was greeted more skeptically. Reports of the successes 
of 3D CRT compared with traditional 2D treatments conﬁrmed the 
beneﬁt ﬁrst demonstrated in comparative treatment planning studies. 
Randomized trials showed improved outcomes both in higher tumor 
control probabilities and lower normal tissue effects. Single institution 
trials with IMRT have shown it possible to increase total doses even to 
higher levels than with 3D CRT with very low complication rates. Re-
cent results (non randomized) have demonstrated decreased pulmonary 
toxicity using IMRT for cancer of the lung compared with 3D CRT. 
IGRT now encompasses advanced techniques of patient immobilization 
and veriﬁcation (orthogonal images prior to treatment each day com-
pared with images from treatment planning). Means of imaging tumors 
after patients are positioned have been developed with ultrasound and 
CT. Methods of coping with tumor motion between and during treat-
ments have been implemented including 4d CT (capturing the images 
of the tumor while breathing, for example), respiratory gating, and 
ﬂuoroscopic tracking of ﬁducial markers near the tumor as the most 
sophisticated form of gating.
The lessons learned from improved tumor control and normal tissue 
avoidance with 3D CRT and IMRT support the continued evolution of 
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IGRT to particle therapy. Proton therapy offers dosimetric advantages 
not possible with x-rays but with a relative biologic effectiveness quite 
close to photons. Thus, normal tissue tolerances can rely on 100 years 
of laboratory and clinical experiences. Well-established indications for 
proton therapy include ocular melanomas, cancer in children, brain 
tumors, sarcomas and chordomas at the base of the skull and carcinoma 
of the prostate. There are many opportunities for proton therapy with 
concurrent chemotherapy to improve the therapeutic ratio compared 
with x-irradiation. There is considerable potential to increase doses 
in tumors without increasing toxicity for common diseases such as 
cancer of the lung. The value of proton therapy is just beginning to be 
recognized.
Interest in proton therapy has increased dramatically around the world. 
Japan alone has six clinical proton therapy centers. Four hospital-based 
proton centers are treating patients in the United States and several 
others are being planned. The beneﬁcial results of 3D over 2D RT, and 
of IMRT over 3DCRT contribute to a compelling case for proton beam 
therapy. As proton therapy equipment becomes less costly and smaller 
and results of proton therapy are published, one can envision a robust 
role for proton beam therapy in the future of cancer treatment.
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Systemic therapy improves survival and quality of life for patients 
with advanced stage non-small cell lung cancer (NSCLC). It became 
clear that infact a ëchemotherapy efﬁcacy plateauí had been reached 
when comparison of multiple two-drug combinations failed to show 
any beneﬁt of one over another. The role of prolonged or maintenance 
therapy beyond 3-6 cycles was challenged by the results from two 
large randomized phase III studies, but there was an apparent ﬂaw as 
majority of the patients randomized to longer duration of chemotherapy 
did not receive the planned number of cycles, leading to discontinua-
tion either due to toxicity or disease progression. Therefore, one could 
only conclude that continuation of combination chemotherapy (two or 
three drugs) beyond 4 cycles is not a feasible option. A number of new 
therapeutic options have subsequently emerged during recent times 
for advanced NSCLC incorporating novel cytotoxic agents (taxanes, 
gemcitabine, pemetrexed) and targeted agents (erlotinib, bevacizumab). 
Efforts to improve the outcome for front-line therapy of advanced and 
metastatic NSCLC have primarily focused on the addition of molecu-
larly targeted agents to platinum-based two drug regimens. Bevaci-
zumab, an antibody against the vascular endothelial growth factor, is 
the ﬁrst drug to demonstrate improvement in outcome when added to 
systemic chemotherapy in advanced disease. Since bevacizumab was 
given as monotherapy following initial response or disease stabilization 
on ECOG 4599, it is now used in the maintenance setting for advanced 
NSCLC. This has led to new insight and a glimmer of hope debate 
for the role of maintenance therapy in advanced NSCLC, provided it 
is not associated with any signiﬁcant long term adverse effects. Both 
cytotoxic single agents and molecularly targeted agents are suited for 
evaluation in the maintenance setting. Promising results have been 
noted with single agent paclitaxel as maintenance therapy following 4 
cycles of combination therapy with carboplatin and paclitaxel. Phase 
III studies are now underway to evaluate the role of single agents such 
as gemcitabine, pemetrexed and erlotinib(ﬁgures 1-3) as maintenance 
therapy for patients who experience a response or disease stabilization 
following 4 cycles of combination chemotherapy. Whether this ap-
proach will be successful in extending the survival of a select group of 
patients remains to be seen. It does, in fact, takes maximal advantage of 
either known active agents in this disease or novel agents which have 
shown early evidence of provocative activity.
In addition to the evaluation of newer agents to improve the outcome 
for advanced NSCLC, maintenance therapy represents a novel strategy 
to increase the therapeutic potential of currently available agents and 
commonly used regimens. Multiple lines of evidence from recent 
observations suggest that maintenance therapy with well tolerated che-
motherapeutic or targeted agents may beneﬁt patients with advanced 
NSCLC. This also has the potential to improve the toxicity proﬁle of 
overall treatment as combination chemotherapy would then be limited 
to 4 cycles and maintenance therapy would be essentially without any 
signiﬁcant adverse effects if chosen optimally. Since maintenance ther-
apy utilizes currently available agents, it may also be associated with 
better cost-beneﬁt ratio. In the next 1-2 years, the results from several 
ongoing trials that focus on maintenance therapy will be available. It is 
hoped that the data will usher in a new treatment paradigm for patients 
with advanced stage NSCLC.
